# A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia

> **NCT02226198** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 20 (actual)

## Conditions studied

- Homozygous Familial Hypercholesterolemia (HoFH)

## Interventions

- **DRUG:** Rosuvastatin 20mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02226198
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2016-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02226198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02226198, "A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02226198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*